(HealthDay News) – The risk of intussusception is not increased in infants aged 4–34 weeks who receive the pentavalent rotavirus vaccine (RV5) compared with infants who do not receive the vaccine, according to research published in the Feb. 8 issue of the Journal of the American Medical Association.
Irene M. Shui, ScD, of the Harvard School of Public Health in Boston, and colleagues conducted a prospective cohort study involving infants aged 4–34 weeks, who received the RV5, to evaluate the risk of intussusception in the first seven or 30 days following vaccination. Data were collected for 786,725 total RV5 doses, including 309,844 first doses, administered from May 2006–February 2010.
The investigators observed no significant increase in the risk of intussusception following RV5 vaccination in the seven- or 30-day risk windows. In the one- to 30-day window, 21 cases were observed, compared with an expected number of 20.9 cases. In the one- to seven-day window, four cases were observed, compared with 4.3 expected cases. For first doses, seven cases were observed versus an expected 5.7 in the one- to seven-day window, and one case was observed versus an expected 0.8 in the one- to 30-day window.
“With almost 800,000 doses of RV5 vaccine administered, including more than 300,000 first doses, we did not find an increased risk of intussusception following RV5 vaccination in either the one- to 30-day or one- to seven-day risk windows,” the authors write.
One of the study authors disclosed financial ties to the pharmaceutical industry.